Healthcare, M&A

Bryan, Garnier & Co acts as Sole Financial Advisor to German medical device CRO/CDMO seleon GmbH

Founded in 1998, seleon GmbH is a renowned German development, consulting, and production service provider for medical technology companies.

Since its acquisition by D11Z Ventures (formerly Zukunftsfonds Heilbronn) in 2007, seleon GmbH has successfully built on its engineering DNA to become one of the few integrated full-service providers in Germany. The company supports businesses of all sizes along the entire value chain – from product development to clinical and regulatory affairs to manufacturing. It serves some of the world’s largest and most innovative medical device OEMs, with expertise in active devices and fluidics applications. Notable customers include Fresenius, Siemens Healthineers, and Paul Hartmann.

seleon will join aesco SOLUTIONS, the growth platform of German private equity fund Aurelius, for medical device CDMO services. By joining brands such as SASSE Elektronik and FG Elektronik, this transaction will create a new European MedTech CDMO champion.

Bryan, Garnier & Co acts as Sole Financial Advisor to seleon and its shareholders.

Bryan, Garnier & Co ran a competitive international M&A process targeting strategic players in the Medtech CDMO and CRO space from both sides of the Atlantic as well as private equity investors specialised in healthcare. As a result, seleon and its shareholders selected aesco SOLUTIONS and its financial sponsor Aurelius as the best partner for the next chapter of the company’s growth story.

This transaction leveraged our fully integrated and international healthcare platform of 7 offices. It is a testimony of our expertise in supporting local champions in the CRO and CDMO sectors to find the ideal partner to bring them to the next stage and reaffirms our positioning as a leading advisor for healthcare mid-cap growth companies across Europe.

"This strategic operation marks a tremendous milestone for seleon. Bryan Garnier’s team demonstrated in-depth market knowledge and facilitated an efficient process with relevant investors. We are convinced aesco SOLUTIONS is the best partner for the next chapter of seleon's growth story and anticipate significant mutual benefits from the combination, creating a leading German Medical Device CDMO."

— Alexander Hofer, Investment Director at D11Z Ventures

Founded in 1998, seleon is a leading German CDMO specialised in providing comprehensive engineering, consulting, and production services to international medical device manufacturers.

With a 26-year commercial track record, seleon supports its customers throughout the entire product life cycle from concept design to production of the finished products, including the development of complex active medical technology systems, the consultation on all regulatory, clinical and QM topics, and the small to medium scale production of medical devices.

Headquartered in Heilbronn, Germany, seleon operates in three locations across the country, employing close to 40 engineers and 90 employees in total.

Headquartered in Germany, aesco SOLUTIONS group was formed by German private equity fund Aurelius in Spring 2023 as a CDMO platform in the medical device space. With brands such as SASSE Elektronik and FG Elektronik, aesco SOLUTIONS offers the expertise, capacities and technologies to successfully support the development and manufacturing of medical technology devices.

The group currently employs more than 100 people across its sites in Germany.

AURELIUS Group is a pan-European investment group with offices in Munich, Düsseldorf, Frankfurt, Hamburg, London, Stockholm, Amsterdam, Madrid, Milan, Luxembourg and Miami. It invests through its investment companies AURELIUS Equity Opportunities and AURELIUS Growth Investments in a variety of different sectors. The AURELIUS Group currently owns more than 35 portfolio companies in Europe, which together generate approximately € 4.0 billion in sales.

AURELIUS Growth Investments is a medium-sized investment holding company that specialises in the acquisition of healthy and growing medium-sized companies with good market positioning.